Lisa Ma, MD
Family Medicine · Los Angeles, CANPI 1639125487
Payments from drug & device makers
Across 169 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$368
- Johnson & Johnson$353
- Lilly USA, LLC$327
- Novo Nordisk$250
- AstraZeneca$248
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,663100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $1,183 |
| Amgen(2 entities) | 8 | $368 |
| Johnson & Johnson | 13 | $353 |
| Lilly USA, LLC | 15 | $327 |
| Novo Nordisk | 10 | $250 |
| AstraZeneca | 6 | $248 |
| Merck | 8 | $209 |
| Corcept Therapeutics | 8 | $197 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $175 |
| Novartis | 7 | $153 |
| AMAG Pharmaceuticals, Inc. | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 1 | $120 |
| Aimmune Therapeutics, Inc. | 4 | $105 |
| Boehringer Ingelheim | 4 | $93 |
| Exact Sciences | 3 | $88 |
| Medtronic | 4 | $78 |
| Pfizer | 3 | $71 |
| Phadia US Inc. | 4 | $63 |
| Bayer | 2 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| GSK | 2 | $49 |
| Amarin Pharma, Inc. | 2 | $45 |
| Abbott | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Zealand Pharma US, Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
| Valeritas, Inc. | 1 | $13 |
| Therapeuticsmd, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,663 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $88,909 |
| XareltoRivaroxaban | 242 | $83,419 |
| EliquisApixaban | 195 | $68,023 |
| JanuviaSitagliptin Phosphate | 106 | $51,662 |
| TrulicityDulaglutide | 33 | $42,274 |
| JardianceEmpagliflozin | 92 | $32,141 |
| VascepaIcosapent Ethyl | 33 | $30,829 |
| FarxigaDapagliflozin Propanediol | 31 | $30,107 |
| EntrestoSacubitril/Valsartan | 69 | $28,993 |
| CreonLipase/Protease/Amylase | 12 | $27,904 |
| MounjaroTirzepatide | 25 | $27,052 |
| SantylCollagenase Clostridium Hist. | 25 | $22,548 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 52 | $15,540 |
| Atorvastatin Calcium | 682 | $12,272 |
| LinzessLinaclotide | 41 | $11,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto, Invokana | $353 | $90,602255 claims |
| Novo NordiskOzempic | $250 | $88,90972 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $327 | $69,32658 claims |
| PfizerEliquis | $71 | $68,023195 claims |
| MerckJanuvia | $209 | $51,662106 claims |
| AbbVieCreon, Linzess, Lumigan | $1,183 | $43,74870 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $93 | $38,392103 claims |
| AstraZenecaFarxiga | $248 | $30,10731 claims |
| NovartisEntresto | $153 | $28,99369 claims |
| GSKArexvy | $49 | $15,54052 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $49 | $8,12114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Los Angeles
- Albert NassirLos Angeles$5.7M
- Nader SobhLos Angeles$4.1M
- Alexander RivkinLos Angeles$2.8M
- Pamela KushnerLos Angeles$1.2M
- Scott HowellLos Angeles$793K
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.